Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.75 |
| ▸ | HTR2A | P28223 | 5/20 | 0.52 |
| ▸ | HTR2B | P41595 | 3/20 | 0.52 |
| ▸ | HTR1A | P08908 | 2/20 | 0.52 |
| ▸ | HTR2C | P28335 | 2/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.52 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.49 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.49 |
| ▸ | MPO | P05164 | 1/20 | 0.45 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.44 |
| ▸ | HTR1D | P28221 | 1/20 | 0.44 |
| ▸ | HTR1B | P28222 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30630326 | 0.86 | HTR6 (1.00) | HTR6HTR2AHTR2BHTR1AHTR2C | |
| SCHEMBL27085094 | 0.86 | HTR6 (1.00) | HTR6HTR2AHTR2BHTR1AHTR2C | |
| SCHEMBL14961010 | 0.85 | HTR2A (0.56) | HTR6HTR2ASLC6A4LTA4HPLA2G2A | |
| SCHEMBL14907351 | 0.83 | HTR2A (0.74) | HTR6HTR2AHTR1AHTR2CSLC6A4 | |
| SCHEMBL11539380 | 0.83 | HTR2A (0.54) | HTR6HTR2ASLC6A4LTA4HPLA2G2A | |
| SCHEMBL27084740 | 0.82 | HTR6 (0.68) | HTR6HTR2AHTR2BHTR1AHTR2C | |
| SCHEMBL30630327 | 0.82 | HTR6 (0.68) | HTR6HTR2AHTR2BHTR1AHTR2C | |
| SCHEMBL23211671 | 0.81 | HTR6 (0.71) | HTR6HTR2AHTR2BHTR1AHTR2C | |
| SCHEMBL30630330 | 0.80 | HTR6 (0.70) | HTR6HTR2AHTR2BHTR1AHTR2C | |
| SCHEMBL27085080 | 0.80 | HTR6 (0.70) | HTR6HTR2AHTR2BHTR1AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150306077-A1 | Novel Compositions and Methods for Treating Cancer | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2015-10-29 | — | — | US | disclosed |
| US-9073851-B2 | Compositions and methods for treating cancer | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2015-07-07 | — | — | US | disclosed |
| US-20130129812-A1 | NOVEL COMPOSITIONS AND METHODS FOR TREATING CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-05-23 | — | — | US | disclosed |
| WO-2013063492-A1 | NOVEL COMPOSITIONS AND METHODS FOR TREATING CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150306077-A1 | Novel Compositions and Methods for Treating Cancer | HDGF, HCCS, CCNC | HTR6 139/4885HTR2A 94/4885HTR2B 367/4885 |
| US-20130129812-A1 | NOVEL COMPOSITIONS AND METHODS FOR TREATING CANCER | HDGF, HCCS, CCNC | HTR6 139/4885HTR2A 94/4885HTR2B 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.